Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
The original release is unavailable here.
Earlier from Rakovina Therapeutics
- Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
- Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors
- Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update
- Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement